The meta-analyses demonstrated that, for patients with atherosclerotic cardiovascular disease (ASCVD), ezetimibe added to statin therapy provided an additional reduction of 22 mg/dL in low-density lipoprotein cholesterol (LDL-C) compared with statin monotherapy.

LDL-C > 70 mg/dL is considered a threshold at which additional LDL-C-lowering therapy may be needed in patients with ASCVD and at very high risk of recurrent events; the magnitude of the incremental reduction in LDL-C with ezetimibe observed here may not be sufficient for many patients.